Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer

被引：0

作者：

Zhifei Li ^{[1
]}

Huan Zhao ^{[2
]}

Huihui Hu ^{[1
]}

Haili Shang ^{[1
]}

Yongjing Ren ^{[1
]}

Wenhui Qiu ^{[3
]}

Hao Su ^{[4
]}

Huifang Lyu ^{[5
]}

Xiaobing Chen ^{[1
]}

机构：

[1] Department of Oncology, the Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital, Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer, Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Canc

[2] Henan University of Traditional Chinese Medicine

[3] State Key Laboratory of Esophageal Cancer Prevention&Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, School of Pharmaceutical Sciences,Zhengzhou University

[4] The First Affiliated Hospital of Xinxiang Medical University

[5] Department of Oncology, the Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer

来源：

Chinese Journal of Cancer Research | 2024年 / 36卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R735.2 [胃肿瘤];

学科分类号：

摘要：

Gastric cancer is one of the most prevalent cancers worldwide, and human epidermal growth factor receptor 2(HER2)-positive cases account for approximately 20% of the total cases. Currently, trastuzumab + chemotherapy is the recommended first-line treatment for patients with HER2-positive advanced gastric cancer, and the combination has exhibited definite efficacy in HER2-targeted therapy. However, the emergence of drug resistance during treatment considerably reduces its effectiveness; thus, it is imperative to investigate the potential mechanisms underlying resistance. In the present review article, we comprehensively introduce multiple mechanisms underlying resistance to trastuzumab in HER2-positive gastric cancer cases, aiming to provide insights for rectifying issues associated with resistance to trastuzumab and devising subsequent treatment strategies.

引用

页码：306 / 321

页数：16

共 50 条

[41] Duration of trastuzumab for HER2-positive breast cancer
Montemurro, Filippo
Aglietta, Massimo
LANCET ONCOLOGY, 2013, 14 (08): : 678 - 679
[42] Phase II study of trastuzumab with irinotecan in HER2-positive gastric cancer previously treated with trastuzumab
Hatanaka, Kazuteru
Kawamoto, Yasuyuki
Yuki, Satoshi
Meguro, Takashi
Uebayashi, Minoru
Abe, Masakazu
Nakamura, Michio
Okuda, Hiroyuki
Sakata, Yuh
Komatsu, Yoshito
ANNALS OF ONCOLOGY, 2017, 28
[43] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Volkmar Müller
Michael Clemens
Jacek Jassem
Nedal Al-Sakaff
Petra Auclair
Eveline Nüesch
Debbie Holloway
Mona Shing
Yung-Jue Bang
BMC Cancer, 18
[44] Trastuzumab (herceptin) and HER2-positive breast cancer
Murray, S
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (01) : 36 - 37
[45] Trastuzumab emtansine for HER2-positive breast cancer
Venkatesan, Priya
LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
[46] Adjuvant trastuzumab for HER2-positive breast cancer
Spicer, J
Harries, M
Ellis, P
LANCET, 2005, 366 (9486): : 634 - 634
[47] HER2-Positive Breast Cancer: Beyond Trastuzumab
Murphy, Conleth G.
Fornier, Monica
ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415
[48] Dissecting the molecular mechanism of trastuzumab resistance in stage IV HER2-positive gastric cancer patients.
Xu, Qi
Li, Jingjing
Tang, Haimeng
Bao, Hua
Yan, Junrong
Wu, Xue
Shao, Yang
Jin, Jianying
Luo, Cong
Weng, Haimin
Ying, Jieer
CANCER RESEARCH, 2022, 82 (12)
[49] Pathologic Response of HER2-positive Gastric Cancer to Trastuzumab-based Chemotherapy
Urabe, Masayuki
Ushiku, Tetsuo
Seto, Yasuyuki
Fukayama, Masashi
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2016, 40 (10) : 1326 - 1333
[50] Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer
Ock, Chan-Young
Lee, Keun-Wook
Kim, Jin Won
Kim, Jin-Soo
Kim, Tae-Yong
Lee, Kyung-Hun
Han, Sae-Won
Im, Seock-Ah
Kim, Tae-You
Kim, Woo Ho
Bang, Yung-Jue
Oh, Do-Youn
CLINICAL CANCER RESEARCH, 2015, 21 (11) : 2520 - 2529

← 1 2 3 4 5 →